Takanashi Ken's Form 4 filing
Satsuma Pharmaceuticals, Inc.STSA · filed Jun 8, 2023
- Accession no.
- 0000899243-23-014896
- Filed
- Jun 8, 2023
- Trade date
- Jun 6-8, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 3 derivative transactions. Open-market purchases total $20.1M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Takanashi KenCIK 0001657768 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 6, 2023 | Common Stock, $0.0001 par value | PPurchaseAcquired | +22,053,581 | $0.91 | +$20,068,758.71 | 24,847,694 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 8, 2023 | Common Stock | DReturned to the companyDisposed | −10,000 | $0.00F5 | $0 | 0 | Direct | |
| Jun 8, 2023 | Common Stock | DReturned to the companyDisposed | −20,000 | $0.00F5 | $0 | 0 | Direct | |
| Jun 8, 2023 | Common Stock | DReturned to the companyDisposed | −30,000 | $0.00F5 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F5
Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration.
Referenced by the price of 3 transactions in Table II.